Harlow, UK-based Argenta Discovery has initiated a clinical trial with ADC4022, an investigational medicine for the treatment of chronic obstructive pulmonary disease and severe asthma. The Phase I study is scheduled to enroll 36 healthy volunteers with ADC4022 dosed by inhalation and is designed to assess the tolerability and pharmacokinetics of single and multiple doses of the agent when given alone or co-administered with marketed inhaled corticosteroids.
Preclinical studies undertaken by Argenta indicate that ADC4022 and inhaled corticosteroids have little effect on lung inflammation when given separately, but are synergistic combined.
Christopher Ashton, Argenta's chief executive, stated that the firm hopes to commence a pilot Phase II efficacy study in patients with COPD next year after successfully completing this Phase I trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze